Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
X-PEG-PAL
- Development stage
- Preclinical
- Lead developer
- SunBio
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
X-PEG-PAL is a PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme being developed by SunBio for the treatment of phenylketonuria (PKU). PKU is a rare metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, leading to the accumulation of phenylalanine to neurotoxic levels. X-PEG-PAL serves as an enzyme replacement therapy that bypasses the deficient hydroxylase pathway by converting phenylalanine into trans-cinnamic acid and ammonia, which are then excreted. The addition of polyethylene glycol (PEG) moieties to the PAL enzyme is designed to enhance its stability, reduce immunogenic potential, and prolong its half-life in circulation, potentially offering a therapeutic option for patients who require significant reduction in blood phenylalanine levels.
- Other names
- PEGylated phenylalanine ammonia lyasePEG-PAL
Beyond the preview
Go deeper on X-PEG-PAL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on X-PEG-PAL.